TRIA Bioscience Corp

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with TRIA Bioscience

Contact TRIA Bioscience, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Articles

Construction of an enantiopure bivalent nicotine vaccine using synthetic peptides

Jun 01, 2017 |

By David F. Zeigler, TRIA Bioscience Corp, Richard Roque, Christopher H. Clegg

| PLOS

Clinical outcomes of anti-nicotine vaccines may be improved through enhancements in serum antibody affinity and concentration. Two strategies were explored to improve vaccine efficacy in outbred mice: the use of enantiopure haptens and formulation of a bivalent vaccine.

Open in Who Shared

See all 1 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Get in touch with TRIA Bioscience

Contact TRIA Bioscience, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

For PR Teams

Overview

Use Cases

Capabilities

Industries

Introducing Curation Engine

Resources

Library

Commmunity

Customers

Company

TRIA Bioscience Corp

Get in touch with TRIA Bioscience

Actions

Is this you?

Articles

Construction of an enantiopure bivalent nicotine vaccine using synthetic peptides

Actions

Is this you?

Get in touch with TRIA Bioscience